Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient

References

• Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R (2000). Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167–1175.
   Google Scholar
• Ding YH, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC (1998). Two human T-cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 8: 403–411.
   PubMed Web of Science ®Google Scholar
• Evavold BD, Allen PM (1991). Separation of IL-4 produc-tion from Th cell proliferation by an altered T-cell re-ceptor ligand. Science 252: 1308–1310.
   PubMed Web of Science ®Google Scholar
• Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G (1985). Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2: 407–410.
   PubMed Web of Science ®Google Scholar
• Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R (1999). Molecular mimicry and multiple sclerosis: de-generate T-cell recognition and the induction of autoim-munity. Ann Neurol 45: 559–567.
   PubMedGoogle Scholar
• Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP (1998). Direct visualization of antigen-specific T-cells: HTLV-1 Tax11-19-specific CD8+ T-cells are activated in periph-eral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Nat] Acad Sci USA 95: 7568–7573.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Vergelli M, Tranquill L, Conlon P, Ling N, McFarland HF, Martin R (1997). Human T-cell re-sponse to myelin basic protein peptide (83–99): exten-sive heterogeneity in antigen recognition, function, and phenotype. Neurology 49: 1116–1126.
   Google Scholar
• Jacobson S (1996). Cellular immune responses to HTLV-I: immunopathogenic role in HTLV-I-associated neuro-logic disease. J Acquir Immune Defic Syndr Hum Retro-virol 13: S100-S106, Suppl. 1.
   Google Scholar
• Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S (1990). Circulating CD8+ cytotoxic T lymphocytes spe- cific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348: 245–248.
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L, the altered peptide ligand in relapsing MS study group (2000). Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide fig-and in a placebo-controlled, randomized phase II trial. Nat Med 6: 1176–1182.
   PubMed Web of Science ®Google Scholar
• Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S (1998). Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/ tropical spastic paraparesis patients by intracellular cy-tokine detection. J Immunol 161: 482–488.
   PubMed Web of Science ®Google Scholar
• Kubota R, Soldan SS, Martin R, Jacobson S (2000). An al-tered peptide ligand antagonizes antigen-specific T cells of patients with human T lymphotropic virus type I-associated neurological disease. I Immunol 164: 5192–5198.
   Google Scholar
• Levin MC, Lehky TJ, Flerlage AN, Katz D, Kingma DW, Jaffe ES, Heiss JD, Patronas N, McFarland HF, Jacobson S (1997). Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease. N Engl J Med 336: 839–845.
   PubMedGoogle Scholar
• Moritoyo T, Izumo S, Moritoyo H, Tanaka Y, Kiyomatsu Y, Nagai M, Usuku K, Sorimachi M, Osame M (1999). De-tection of human T-lymphotropic virus type I p4Otax protein in cerebrospinal fluid cells from patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J NeuroVirol 5: 241–248.
   Google Scholar
• Moritoyo T, Reinhart TA, Moritoyo H, Sato E, Izumo S, Osame M, Haase AT (1996). Human T-lymphotropic virus type I-associated myelopathy and tax gene expres-sion in CD4+ T lymphocytes. Ann Neurol 40: 84–90.
   PubMedGoogle Scholar
• Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, Tara M, Igata A (1987). Chronic progres-sive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol 21: 117–122.
   PubMed Web of Science ®Google Scholar
• Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M (1986). HTLV-I associated myelopathy, a new clinical entity. Lancet 1: 1031–1032.
   Google Scholar
• Umehara F, Izumo S, Nakagawa M, Ronquillo AT, Takahashi K, Matsumuro K, Sato E, Osame M (1993). Im-munocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopa-thy. J Neuropathol Exp Neurol 52: 424–430.
   Google Scholar
• Utz U, Banks D, Jacobson S, Biddison WE (1996). Anal-ysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cy-totoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion. I Virol 70: 843–851.
   PubMedGoogle Scholar
• Utz U, Brooks JA, McFarland HF, Martin R, Biddison WE (1994). Heterogeneity of T-cell receptor alpha-chain complementarity-determining region 3 in myelin basic protein-specific T-cells increases with severity of multi-ple sclerosis. Proc Nat] Acad Sci USA 91: 5567–5571.
   Google Scholar